|
1
|
Chang AE, Karnell LH and Menck HR: The
national cancer database report on cutaneous and noncutaneous
melanoma: A summary of 84,836 cases from the past decade. The
American college of surgeons commission on cancer and the American
cancer society. Cancer. 83:1664–1678. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fujimoto M, Matsuzaki I, Nishitsuji K,
Yamamoto Y, Murakami D, Yoshikawa T, Fukui A, Mori Y, Nishino M,
Takahashi Y, et al: Adipophilin expression in cutaneous malignant
melanoma is associated with high proliferation and poor clinical
prognosis. Lab Invest. 100:727–737. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mastoraki A, Schizas D, Giannakodimos I,
Rebakos A, Margaris I, Katsaros I, Vagios I, Vassiliu P and
Pikoulis E: Malignant melanoma of the breast: Controversies in the
diagnosis and therapeutic management of a rare nosologic entity.
Int J Dermatol. 59:1057–1064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amalinei C, Grigoraș A, Lozneanu L,
Căruntu ID, Giușcă SE and Balan RA: The interplay between tumour
microenvironment components in malignant melanoma. Medicina
(Kaunas). 58:3652022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Puyana C, Denyer S, Burch T, Bhimani AD,
Mcguire LS, Patel AS and Mehta AI: Primary malignant melanoma of
the brain: A population-based study. World Neurosurg.
130:e1091–e1097. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang K, Oak ASW, Slominski RM, Brożyna AA
and Slominski AT: Current molecular markers of melanoma and
treatment targets. Int J Mol Sci. 21:35352020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi YF, Chen YQ, Chen HF and Hu X: An
atypical primary malignant melanoma arising from the cervical nerve
root: A case report and review of literture. World J Clin Cases.
10:381–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iga T, Iwanami A, Funakoshi T, Mikami S,
Tsuji O, Nagoshi N, Okada E, Fujita N, Yagi M, Watanabe K, et al:
Multifocal primary melanoma of the cervical spinal cord
successfully treated by tumorectomy: A case report. Spinal Cord Ser
Cases. 4:242018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong
SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes
cell glycolysis, growth, migration, and invasion in non-small cell
lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liubinas SV, Maartens N and Drummond KJ:
Primary melanocytic neoplasms of the central nervous system. J Clin
Neurosci. 17:1227–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pappenheim E and Bhattacharji SK: Primary
melanoma of the central nervous system. Clinical-pathological
report of a case, with survey and discussion of the literature.
Arch Neurol. 7:101–113. 1962. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamasaki T, Kikuchi H, Yamashita J, Asato
R and Fujita M: Primary spinal intramedullary malignant melanoma:
Case report. Neurosurgery. 25:117–121. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayward RD: Malignant melanoma and the
central nervous system. A guide for classification based on the
clinical findings. J Neurol Neurosurg Psychiatry. 39:526–530. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujimori K, Sakai K, Higashiyama F, Oya F,
Maejima T and Miyake T: Primary central nervous system malignant
melanoma with leptomeningeal melanomatosis: A case report and
review of the literature. Neurosurg Rev. 41:333–339. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodriguez y Baena R, Gaetani P, Danova M,
Bosi F and Zappoli F: Primary solitary intracranial melanoma: Case
report and review of the literature. Surg Neurol. 38:26–37. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohn-Cedermark G, Mansson-Brahme E,
Rutqvist LE, Larsson O, Johansson H and Ringborg U: Central nervous
system metastases of cutaneous malignant melanoma-a
population-based study. Acta Oncol. 37:463–470. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Vries E and Coebergh JWW: Melanoma
incidence has risen in Europe. BMJ. 331:6982005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang HY, Park N, Erlandson RA and
Antonescu CR: Immunohistochemical and ultrastructural comparative
study of external lamina structure in 31 cases of cellular,
classical, and melanotic schwannomas. Appl Immunohistochem Mol
Morphol. 12:50–58. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Küsters-Vandevelde HVN, van Engen-van
Grunsven IACH, Küsters B, van Dijk MR, Groenen PJTA, Wesseling P
and Blokx WAM: Improved discrimination of melanotic schwannoma from
melanocytic lesions by combined morphological and GNAQ mutational
analysis. Acta Neuropathol. 120:755–764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Küsters-Vandevelde HVN, Küsters B, van
Engen-van Grunsven ACH, Groenen PJTA, Wesseling P and Blokx WAM:
Primary melanocytic tumors of the central nervous system: A review
with focus on molecular aspects. Brain Pathol. 25:209–226. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carney JA: Psammomatous melanotic
schwannoma. A distinctive, heritable tumor with special
associations, including cardiac myxoma and the Cushing syndrome. Am
J Surg Pathol. 14:206–222. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodriguez FJ, Stratakis CA and Evans DG:
Genetic predisposition to peripheral nerve neoplasia: Diagnostic
criteria and pathogenesis of neurofibromatoses, Carney complex, and
related syndromes. Acta Neuropathol. 123:349–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rothenbuhler A and Stratakis CA: Clinical
and molecular genetics of Carney complex. Best Pract Res Clin
Endocrinol Metab. 24:389–399. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balakrishnan R, Porag R, Asif DS, Satter
AMR, Taufiq M and Gaddam SSK: Primary intracranial melanoma with
early leptomeningeal spread: A case report and treatment options
available. Case Rep Oncol Med. 2015:2938022015.PubMed/NCBI
|
|
25
|
Salpietro FM, Alafaci C, Gervasio O, La
Rosa G, Baio A, Francolini DC, Batolo D and Tomasello F: Primary
cervical melanoma with brain metastases. Case report and review of
the literature. J Neurosurg. 89:659–666. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Troya-Castilla M, Rocha-Romero S,
Chocrón-González Y and Marquez-Rivas FJ: Primary cerebral malignant
melanoma in insular region with extracranial metastasis: Case
report and review literature. World J Surg Oncol. 14:2352016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Guo ZZ, Wang YJ, Zhang SG and Xing
DG: Microsurgery for the treatment of primary malignant
intracranial melanoma: A surgical series and literature review. Eur
J Surg Oncol. 40:1062–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma Y, Gui Q and Lang S: Intracranial
malignant melanoma: A report of 7 cases. Oncol Lett. 10:2171–2175.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Young GJ, Bi WL, Wu WW, Johanns TM, Dunn
GP and Dunn IF: Management of intracranial melanomas in the era of
precision medicine. Oncotarget. 8:89326–89347. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Swetter SM, Thompson JA, Albertini MR,
Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham
A, Fields RC, et al: NCCN guidelines® insights:
Melanoma: Cutaneous, version 2.2021. J Natl Compr Canc Netw.
19:364–376. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han CH and Brastianos PK: Genetic
characterization of brain metastases in the era of targeted
therapy. Front Oncol. 7:2302017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jour G, Ivan D and Aung PP: Angiogenesis
in melanoma: An update with a focus on current targeted therapies.
J Clin Pathol. 69:472–483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrara N, Hillan KJ, Gerber HP and
Novotny W: Discovery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Corrie PG, Marshall A, Dunn JA, Middleton
MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples
M, et al: Adjuvant bevacizumab in patients with melanoma at high
risk of recurrence (AVAST-M): Preplanned interim results from a
multicentre, open-label, randomised controlled phase 3 study.
Lancet Oncol. 15:620–630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Corrie PG, Marshall A, Nathan PD, Lorigan
P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, et al:
Adjuvant bevacizumab for melanoma patients at high risk of
recurrence: Survival analysis of the AVAST-M trial. Ann Oncol.
30:2013–2014. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ascierto PA, Mandalà M, Ferrucci PF,
Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello
E, Gogas H, et al: Sequencing of ipilimumab plus nivolumab and
encorafenib plus binimetinib for untreated BRAF-mutated metastatic
melanoma (SECOMBIT): A randomized, three-arm, open-label phase II
trial. J Clin Oncol. 41:212–221. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bai X and Zhou M: The benefit of
bevacizumab therapy in patients with refractory vasogenic edema
caused by brain metastasis from lung and colon cancers. Front
Oncol. 12:8386702022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Banks PD, Lasocki A, Lau PKH, Sandhu S,
Mcarthur G and Shackleton M: Bevacizumab as a steroid-sparing agent
during immunotherapy for melanoma brain metastases: A case series.
Health Sci Rep. 2:e1152019. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Markovic SN, Suman VJ, Javed A, Reid JM,
Wall DJ, Erickson LA, Ernstoff M and Anderson DM: Sequencing
ipilimumab immunotherapy before or after chemotherapy
(Nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF
wild-type) metastatic malignant melanoma: Results of a study of
academic and community cancer research United (ACCRU) RU261206I. Am
J Clin Oncol. 43:115–121. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shields CL, Dalvin LA, Chang M, Mazloumi
M, Fortin P, McGarrey M, Martin A, Yaghy A, Yang X, Vichitvejpaisal
P, et al: Visual outcome at 4 years following plaque radiotherapy
and prophylactic intravitreal bevacizumab (every 4 months for 2
years) for uveal melanoma: Comparison with nonrandomized historical
control individuals. JAMA Ophthalmol. 138:136–146. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chinese guidelines for diagnosis and
treatment of melanoma 2018 (English version). Chin J Cancer Res.
31:578–585. 2019. View Article : Google Scholar : PubMed/NCBI
|
